(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 January 2010 (28.01.2010)

PCT

(10) International Publication Number
WO 2010/010190 A1

(51) **International Patent Classification**:
C07D 471/04 (2006.01) ***A61P 19/02*** (2006.01)
A61K 31/437 (2006.01)

(21) **International Application Number**:
PCT/EP2009/059604

(22) **International Filing Date**:
24 July 2009 (24.07.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/135,920	25 July 2008 (25.07.2008)	US
61/220,685	26 June 2009 (26.06.2009)	US

(71) **Applicant** *(for all designated States except US)*: **GALAPAGOS NV** [BE/BE]; Industriepark Mechelen Noord, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **MENET, Christel Jeanne Marie** [FR/FR]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **VAN ROMPAEY, Luc Juliaan Corina** [BE/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **FLETCHER, Stephen Robert** [GB/FR]; Galapagos SASU, 102 Avenue Gaston Roussel, F-93230 Romainville (FR). **BLANC, Javier** [ES/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **JOUANNIGOT, Nolwenn** [FR/FR]; 50 Route de Pringy, F-74940 Annecy le Vieux (FR). **HODGES, Alastair James** [GB/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden Essex CB10 1XL (GB). **SMITS, Koen Kurt** [BE/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE).

(74) **Agent**: **NICHOL, Maria**; Galapagos NV, Chesterford Research Park, Saffron Walden Essex CB10 1XL (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

(54) **Title**: NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES



(I)

(57) **Abstract**: [1,2,4]Triazolo[1,5-*a*]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6, transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

WO 2010/010190 A1